MorphoSys Strengthens Patent Position on its Core Technologies in Japan
First Granted HuCAL-Related Patent in Japan
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Japanese Patent Office has granted a new patent covering its CysDisplay® technology. CysDisplay® is a proprietary screening technology, which is an important component of MorphoSys’s proprietary HuCAL platform. The new patent (JP 4312403) entitled “Novel Methods for Displaying (Poly)Peptides/Proteins on Bacteriophage Particles” describes a selection technology based on phage display for selecting high affinity antibodies. The claims are not limited to the use of a HuCAL library with this selection technology. Additional applications, including continuation applications, are currently pending in different countries.
“This new patent expands the protection of our proprietary core technology HuCAL in Asia. Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL, which lies at the heart of our successful partnership-based business model. We expect to continue to strengthen still further our IP position in this important market for antibody-based products and services,” commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys’s HuCAL libraries are collections of highly diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The company’s most advanced marketed version, HuCAL PLATINUM, provides rapid access to fully human antibodies as research tools, diagnostics and therapeutics. HuCAL patents have been granted in the United States, Australia, and at the European Patent Office. In total, the Company is prosecuting about thirty different proprietary patent families worldwide, which comes in addition to approximately thirty patent families the Company is pursuing in cooperation with its partners.
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, email@example.com or Mario Brkulj, Senior Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, firstname.lastname@example.org
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys’s goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world’s largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.